Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Early Treatment With Interferon Beta-1b Can Delay Progression Of Multiple Sclerosis

03.08.2007
Early treatment of multiple sclerosis (MS) patients with interferon beta-1b can prevent the disabling development of the condition, conclude authors of an Article published in this week’s edition of The Lancet.

Professor Ludwig Kappos University Hospital Petersgraben, Basle, Switzerland, and colleagues, as part of the BENEFIT study, did a study of 468 patients who had shown early symptoms of MS. Of these, 292 were randomised to receive 250µg interferon beta-1b and 176 to receive placebo, subcutaneously every other day for two years, or until they were diagnosed with clinically definite multiple sclerosis (CDMS). After diagnosis of CDMS or completion of two-years of treatment, the patients were then eligible to enter a follow-up phase to receive interferon beta-1b treatment.

Of the patients originally enrolled, 89% entered the follow-up phase, while 84% completed the three-years post-randomisation follow up (2 years in initial phase, one year follow up phase). The study measured patients’ disability status using the expanded disability status scale (EDSS) and found that early treatment with interferon beta-1b reduced the risk for progression of disability by 40% compared with delayed treatment. And whilst 51% of patients in the delayed-treatment group developed CDMS, only 37% of the patients who received early treatment with interferon beta-1b developed CDMS. Thus early treatment reduced the risk of developing CDMS by 41%.

The authors conclude: “Our data suggest that early initiation of treatment with interferon-1b prevents the development of confirmed disability, supporting its use after the first manifestation of relapsing-remitting MS.”

In an accompanying Comment, Dr Sean Pittock, Mayo Clinic of Medicine, Rochester, Minnesota, USA, says: “Kappos and colleagues have set a new standard against which future extension trials will be compared.”

He concludes: “The results should, however, be interpreted with care because the magnitude of benefit, although significant, is clinically small. This follow-up should not be misconstrued as evidence for a treat all approach.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/ms.pdf

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Shallow soils promote savannas in South America

20.10.2017 | Earth Sciences

How Obesity Promotes Breast Cancer

20.10.2017 | Life Sciences

How the smallest bacterial pathogens outwit host immune defences by stealth mechanisms

20.10.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>